Wedbush Equities Analysts Raise Earnings Estimates for KNSA

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) – Wedbush boosted their Q1 2025 earnings per share estimates for Kiniksa Pharmaceuticals in a report issued on Tuesday, February 25th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of $0.31 per share for the quarter, up from their prior forecast of $0.10. Wedbush currently has a “Outperform” rating and a $34.00 target price on the stock. The consensus estimate for Kiniksa Pharmaceuticals’ current full-year earnings is ($0.55) per share. Wedbush also issued estimates for Kiniksa Pharmaceuticals’ Q2 2025 earnings at $0.38 EPS, Q3 2025 earnings at $0.47 EPS, Q4 2025 earnings at $0.52 EPS, FY2025 earnings at $1.69 EPS, FY2026 earnings at $2.55 EPS and FY2027 earnings at $3.24 EPS.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its earnings results on Tuesday, February 25th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.06). The firm had revenue of $122.50 million during the quarter, compared to the consensus estimate of $123.42 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The company’s revenue was up 46.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.35 EPS.

Other equities research analysts have also issued reports about the stock. JPMorgan Chase & Co. lifted their price target on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Evercore ISI lifted their target price on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Kiniksa Pharmaceuticals has an average rating of “Buy” and a consensus target price of $36.60.

Kiniksa Pharmaceuticals Stock Down 0.2 %

Shares of KNSA stock opened at $19.69 on Thursday. Kiniksa Pharmaceuticals has a 12 month low of $16.56 and a 12 month high of $28.15. The company’s fifty day simple moving average is $19.68 and its 200-day simple moving average is $22.57. The firm has a market cap of $1.42 billion, a PE ratio of -140.63 and a beta of 0.32.

Institutional Trading of Kiniksa Pharmaceuticals

A number of hedge funds have recently modified their holdings of the stock. Braidwell LP raised its holdings in Kiniksa Pharmaceuticals by 40.6% in the 3rd quarter. Braidwell LP now owns 2,894,513 shares of the company’s stock valued at $72,334,000 after acquiring an additional 836,210 shares during the period. FMR LLC grew its position in shares of Kiniksa Pharmaceuticals by 36,925.0% in the third quarter. FMR LLC now owns 696,810 shares of the company’s stock valued at $17,413,000 after purchasing an additional 694,928 shares during the last quarter. Jane Street Group LLC increased its stake in shares of Kiniksa Pharmaceuticals by 1,064.4% during the third quarter. Jane Street Group LLC now owns 345,092 shares of the company’s stock worth $8,624,000 after purchasing an additional 315,456 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Kiniksa Pharmaceuticals by 138.9% during the fourth quarter. JPMorgan Chase & Co. now owns 477,800 shares of the company’s stock worth $9,451,000 after purchasing an additional 277,827 shares during the period. Finally, Millennium Management LLC lifted its holdings in Kiniksa Pharmaceuticals by 50.9% during the 4th quarter. Millennium Management LLC now owns 779,672 shares of the company’s stock worth $15,422,000 after purchasing an additional 263,146 shares during the last quarter. Institutional investors and hedge funds own 53.95% of the company’s stock.

Insiders Place Their Bets

In related news, CFO Mark Ragosa sold 8,969 shares of the business’s stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $21.45, for a total transaction of $192,385.05. Following the transaction, the chief financial officer now directly owns 22,958 shares of the company’s stock, valued at approximately $492,449.10. The trade was a 28.09 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Eben Tessari sold 14,000 shares of the stock in a transaction on Monday, January 13th. The shares were sold at an average price of $18.24, for a total value of $255,360.00. Following the completion of the sale, the chief operating officer now owns 88,975 shares in the company, valued at approximately $1,622,904. This trade represents a 13.60 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 38,092 shares of company stock valued at $745,589. 54.57% of the stock is currently owned by corporate insiders.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.